Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus nab-paclitaxel and nedaplatin as neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma
ChiCTR2400083452Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, paclitaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoints: pathological complete response rate and immune microenvironment mechanism affecting immunotherapy efficacy. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimabpaclitaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400083452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083452.